Gallwitz, Baptist

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry

Peptidase Inhibition and AnalysisDiabetes Treatment and Management

Cited by 1,161

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 369

Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects

Meier, J. J., Nauck, M. A., Kranz, D., Holst, J. J., Deacon, C. F., Gaeckler, D., Schmidt, W. E., & Gallwitz, B. (2004) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 334

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 314

Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms

Schäfer, S. A., Tschritter, O., Machicao, F., Thamer, C., Stefan, N., Gallwitz, B., Holst, J. J., Dekker, J. M., t’Hart, L. M., Nijpels, G., et al. (2007) · Diabetologia

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 308

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

Meier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 276

The extra‐pancreatic effects of GLP‐1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems

Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 156

Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents

Gallwitz, B. (2011) · Drugs

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 142

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes

Nauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, J. J., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Meier, J. J. (2004) · Regulatory Peptides

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 137

The glucagon-like peptide-1 metabolite GLP-1-(9–36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans

Meier, J. J., Gethmann, A., Nauck, M. A., Götze, O., Schmitz, F., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Holst, J. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 104

Effect of once‐weekly dulaglutide on glycated haemoglobin ( HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c

Gallwitz, B., Dagogo‐Jack, S., Thieu, V., Garcia‐Perez, L., Pavo, I., Yu, M., Robertson, K. E., Zhang, N., & Giorgino, F. (2018) · Diabetes Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 98

Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes

Meier, J. J., Weyhe, D., Michaely, M., Senkal, M., Zumtobel, V., Nauck, M. A., Holst, J. J., Schmidt, W. E., & Gallwitz, B. (2004) · Critical Care Medicine

Hyperglycemia and glycemic control in critically ill and hospitalized patientsDiabetes Treatment and Management

Cited by 89

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity

Gallwitz, B. (2022) · Frontiers in Endocrinology

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 81

The incretin/glucagon system as a target for pharmacotherapy of obesity

Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 77

Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide

Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 70

Therapy of Type 2 Diabetes

Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 62

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study

Simó, R., Guerci, B., Schernthaner, G., Gallwitz, B., Rosas-Guzmàn, J., Dotta, F., Festa, A., Zhou, M., & Kiljański, J. (2015) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 47

The evolving place of incretin-based therapies in type 2 diabetes

Gallwitz, B. (2010) · Pediatric Nephrology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 42

Therapy of Type 2 Diabetes

Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 12